Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium–glucose co‐transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Aims: Dapagliflozin, a selective, orally active inhibitor of the renal sodium–glucose co‐transporter type 2 (SGLT2) is in development for the treatment of type 2 diabetes mellitus (T2DM). Here, the pharmacokinetics (PK) and pharmacodynamics (PD) of dapagliflozin were evaluated in healthy Japanese subjects and in Japanese subjects with T2DM. Methods: Two studies were conducted: a single‐ascending dose (SAD) study (2.5–50 mg) in 32 healthy subjects and a multiple‐ascending dose (MAD) study (2.5–20 mg QD for 14 days) in 36 subjects with T2DM. Safety and tolerability were assessed in both studies. Single and multiple dose PK of dapagliflozin and its inactive major metabolite, dapagliflozin 3‐ O ‐glucuronide, and PD (urinary glucose parameters) were characterized. Plasma glucose parameters were assessed over 14 days in the MAD study. Results: No serious adverse events or discontinuations due to adverse events occurred in either study. In healthy and T2DM subjects, dapagliflozin was rapidly absorbed with a time to maximum plasma concentration of 0.5–1.3 h. Systemic exposure of dapagliflozin and dapagliflozin 3‐ O ‐glucuronide, measured by maximum plasma concentration and area under the plasma concentration–time curve, increased proportional to dose. On a molar basis, systemic exposure to dapagliflozin 3‐ O ‐glucuronide was similar to parent dapagliflozin. There was a dose‐related increase in the amount of glucose excreted in the urine (SAD and MAD), which was associated with dose‐related decreases in plasma glucose parameters in subjects with T2DM (MAD). Conclusions: Dapagliflozin was well tolerated and showed predictable dose‐proportional PK and PD parameters in both healthy and T2DM Japanese subjects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
List, J. F., Woo, V., Morales, E., Tang, W., & Fiedorek, F. T. (2009) · Diabetes Care · doi:10.2337/dc08-1863 · Cited by 698 · cited 1×
“Clinically, meaningful improvements in glycaemic parameters were observed with oral dapagliflozin in patients with T2DM when administered as a monotherapy [9,10] or as an add-on to either metformin [11] or insulin plus high doses of oral antidiabetic drugs [12].”
BackgroundMeng, W., Ellsworth, B. A., Nirschl, A. A., McCann, P. J., Patel, M., Girotra, R. N., Wu, G., Sher, P. M., Morrison, E. P., Biller, S. A., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701272q · Cited by 634 · cited 1×
“The renal SGLT type 2 (SGLT2) accounts for the majority of glucose reabsorption in the kidney [6] and an orally active, potent and selective inhibitor of SGLT2—dapagliflozin—is under development for the treatment of T2DM [7,8].”
BackgroundKomoroski, B., Vachharajani, N., Feng, Y., Li, L., Kornhauser, D., & Pfister, M. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.250 · Cited by 396 · cited 2×
“These safety and tolerability findings are consistent with SAD and MAD studies conducted in US healthy subjects at single doses of dapagliflozin up to 500 mg or multiple daily doses of up to 100 mg [14] and in US subjects with T2DM administered multiple daily doses of up to 100 mg [13].”
BackgroundResult
Cited by
Hawley, S. A., Ford, R. J., Smith, B. K., Gowans, G. J., Mancini, S. J., Pitt, R. D., Day, E. A., Salt, I. P., Steinberg, G. R., & Hardie, D. G. (2016) · Diabetes · doi:10.2337/db16-0058 · Cited by 391
Wilding, J. P. H., Woo, V., Rohwedder, K., Sugg, J., Parikh, S., & for the Dapagliflozin 006 Study Group (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12187 · Cited by 291
Kasichayanula, S., Liu, X., LaCreta, F., Griffen, S. C., & Boulton, D. W. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0104-3 · Cited by 276
Self-citationLi, D., Wang, T., Shen, S., Fang, Z., Dong, Y., & Tang, H. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12825 · Cited by 253
Mancini, S. J., Boyd, D., Katwan, O. J., Strembitska, A., Almabrouk, T. A., Kennedy, S., Palmer, T. M., & Salt, I. P. (2018) · Scientific Reports · doi:10.1038/s41598-018-23420-4 · Cited by 240
Metadata
- Authors
- Kasichayanula, S., Chang, M., Hasegawa, M., Liu, X., Yamahira, N., LaCreta, F. P., Imai, Y., & Boulton, D. W.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2011-02-23
- Volume
- 13
- Issue
- 4
- Pages
- 357-365
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2060530397
- Cited by
- 115
- References
- 4
- FWCI
- 8.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium–glucose co‐transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus. https://app.cochat.ai/papers/10.1111/j.1463-1326.2011.01359.x
- The paper
- Kasichayanula, S., Chang, M., Hasegawa, M., Liu, X., Yamahira, N., LaCreta, F. P., Imai, Y., & Boulton, D. W. (2011). Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium–glucose co‐transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2011.01359.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.